The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biologic or Conventional Therapy for Early RA?

Biologic or Conventional Therapy for Early RA?

July 19, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2022 (VIRTUAL)—Østergaard et al. compared the radiographic and clinical outcomes of active conventional therapy for patients with rheumatoid arthritis (RA) with the outcomes of patients with RA treated with three biologic therapies with different mechanisms of action. Mikkel Østergaard, MD, Rigshospitalet, Center for Rheumatology and Spine Diseases, Glostrup, Denmark, presented the results of this open-label, blind-assessor study during the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR).1

You Might Also Like
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
  • MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
Explore This Issue
September 2022
Also By This Author
  • FDA Expands Safety Measures for Immediate Release Opioids

To be enrolled in the study (NCT01491815), adult patients had to have treatment-naïve early RA with a symptom duration of less than 24 months and a Disease Activity Score-28 (DAS-28) for RA with C-reactive protein (CRP) of >3.2. Patients also had to have a minimum of two swollen and tender joints, as well as at least one of the following: positivity for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA), and/or a CRP level of >10 mg/L.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers randomized 812 patients, mostly women, with a mean age of 55 years in a 1:1:1:1 ratio to receive 25 mg of methotrexate weekly combined with one of four treatment regimens:

  1. 20 mg of oral prednisolone daily tapered over nine weeks to 5 mg daily, then discontinued at week 36; or 2 g of sulfasalazine daily; or 35 mg/kg of hydroxychloroquine weekly; and mandatory intra-articular glucocorticoid injections in swollen joints (active conventional therapy);
  2. 200 mg of subcutaneous certolizumab pegol administered every other week;
  3. 125 mg of subcutaneous abatacept administered every week; or
  4. tocilizumab administered as four weekly infusions of 8 mg/kg of bodyweight or 162 mg given as a subcutaneous solution weekly.

The primary study outcomes at week 48 were the proportion of patients in remission according to the Clinical Disease Activity Index (CDAI ≤2.8) and a change in the radiographic progression in the total van der Heijde-modified Sharp Score from baseline. The primary end points were estimated using logistic regression and analysis of covariance, adjusted for sex, ACPA status and the country where patients live.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: The adjusted CDAI remission rates at week 48 for each group were:

  • 3% for abatacept;
  • 3% for certolizumab pegol;
  • 9% for tocilizumab; and
  • 2% for active conventional therapy.

Because two primary outcomes were examined, significance was defined as a P value ≤0.25. For the CDAI remission rates of the biologic agents, abatacept (P<0.001) and certolizumab pegol (P=0.021) were superior to active conventional therapy. For CDAI remission rates, the difference in remission rates for tocilizumab did not achieve formal statistical significance (P=0.030). The adjusted mean change in the total modified Sharp-van der Heijde score from baseline was low, indicating no significant differences between the four treatments related to radiographic progression.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: Biologics, early RA, EULAR, EULAR 2022, RA Resource Center, Rheumatoid Arthritis (RA)Issue: September 2022

You Might Also Like:
  • Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients
  • MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • New RA Therapy Promising in Clinical Trial

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)